drugset / Trial / NCT03932955
MC-19PD1 CAR-T in Relapsed or Refractory B Cell Lymphoma
NaSingle-groupOpen-labelTreatment
Summary
This is a single center, single arm, open-lable phase 1 study to determine the safety and efficacy of CD19-CAR-T cells in patients with relapsed or refractory B-cell lymphoma.
Timeline
- Start
- 2019-05-01
- Primary completion
- 2021-05-01
- Completion
- 2021-05-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | MC-19PD1 CAR-T cells | Cell therapy | — | — |